COVID-19 Collection

Journal article

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study

Abstract:: Background

Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to determine the risk associated with its use in routine care in patients with rheumatoid arthritis.

Methods
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Lane, J. C. E., Weaver, J., Kostka, K., Burn, E., Kolovos, S., Prats-Uribe, A., Xie, J., Newby, D., Prieto-Alhambra, D., & consortium, O. H. D. S. I.-C. O. V. I. D.-19. (2020). Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatology, 2(11), E698–E711.

MLA Style

Lane, JCE, et al. “Risk of Hydroxychloroquine Alone and in Combination with Azithromycin in the Treatment of Rheumatoid Arthritis: a Multinational, Retrospective Study.” Lancet Rheumatology, vol. 2, no. 11, 2020, pp. E698–E711.

Chicago Style

Lane, JCE, J Weaver, K Kostka, et al. 2020. “Risk of Hydroxychloroquine Alone and in Combination with Azithromycin in the Treatment of Rheumatoid Arthritis: a Multinational, Retrospective Study.” Lancet Rheumatology 2 (11): E698–E711.
Print

Access Document

Files:: PIIS2665991320302769-VoR.pdf

(Preview, Version of record, pdf, 1.8MB, Terms of use)

Publisher copy:: 10.1016/S2665-9913(20)30276-9

Authors

+ Lane, JCE More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDORMS
Sub department:: Botnar Research Centre
Role:: Author

+ Weaver, J More by this author

Role:: Author

+ Kostka, K More by this author

Role:: Author

+ Burn, E More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDORMS
Role:: Author
ORCID:: 0000-0002-9286-1128

+ Kolovos, S More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDORMS
Role:: Author
ORCID:: 0000-0003-3201-1743

More authors...

+ Arthritis Research UK More from this funder

Grant:: 21605

Publisher:: Elsevier
Journal:: Lancet Rheumatology More from this journal
Volume:: 2
Issue:: 11
Pages:: E698-E711
Publication date:: 2020-08-21
Acceptance date:: 2020-07-21
DOI:: 10.1016/S2665-9913(20)30276-9
EISSN:: 2665-9913

Language:: English
Keywords:: FFR
Pubs id:: 1125347
Local pid:: pubs:1125347
Deposit date:: 2020-08-12
ARK identifier:: ark:/29072/ora_43c5cb211329491685a8e9ce400b3d7b

Terms of use

Copyright holder:: Lane, JCE et al.
Copyright date:: 2020
Rights statement:: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP